Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Current Deferred Revenue came in at $288000.0 in Q2 2025, little changed year-on-year from $288000.0 in Q2 2024, and little changed quarter-over-quarter from $288000.0 in Q1 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $288000.0 for Q2 2025.
- On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $288000.0 in Q2 2025; TTM through Jun 2025 was $288000.0, a 0.0% change from a year earlier, with the FY2024 full-year figure at $288000.0, changed 0.0% from the prior year.
- Current Deferred Revenue steadied at $288000.0 in Q2 2025 per VRDN's latest filing, from $288000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $289000.0 in Q4 2021 and bottomed at $288000.0 in Q1 2021.
- The 5-year median for Current Deferred Revenue is $288000.0 (2021), against an average of $288055.6.
- Across the five-year window, Current Deferred Revenue dropped 3.99% in 2021 and changed 0.0% in 2022, its largest moves.
- Year by year, Current Deferred Revenue stood at $289000.0 in 2021, then dropped by 0.35% to $288000.0 in 2022, then changed by 0.0% to $288000.0 in 2023, then changed by 0.0% to $288000.0 in 2024, then changed by 0.0% to $288000.0 in 2025.
- Per Business Quant, the three latest VRDN Current Deferred Revenue figures stand at $288000.0 (Q2 2025), $288000.0 (Q1 2025), and $288000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 288,000.00 |
| Mar 31, 2025 | 288,000.00 |
| Dec 31, 2024 | 288,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 288,000.00 |
| Jun 30, 2023 | 288,000.00 |
| Mar 31, 2023 | 288,000.00 |
| Dec 31, 2022 | 288,000.00 |
| Sep 30, 2022 | 288,000.00 |
| Jun 30, 2022 | 288,000.00 |
| Mar 31, 2022 | 288,000.00 |
| Dec 31, 2021 | 289,000.00 |
| Sep 30, 2021 | 288,000.00 |
| Jun 30, 2021 | 288,000.00 |
| Mar 31, 2021 | 288,000.00 |
| Dec 31, 2020 | 301,000.00 |